Our academic collaborators’ seminal contributions push the field forward
Our constellation of renowned thinkers and partners
The right collaborators across pharma, biotech and nonprofit
The next generation of scientific leaders in cancer immunotherapy
Stories & Announcements
PICI in the News
Resources for Press
The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies
Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer
All the Right Ingredients: A Q&A with the Founders of ArsenalBio
Develop breakthrough immune therapies to turn all cancers into curable diseases faster
The driving force behind PICI’s research and operations
Transformative science requires visionary philanthropy
Join us. Change lives.
Early Career Researchers
We have an ambitious mission. Not only do we invest in the talent of today, we train the cancer immunotherapy leaders of tomorrow. Our financial support, access to cutting-edge technology, impressive network of scientists, and resources empower the next generation of leaders. With PICI, these early career researchers can take bold questions and big ideas and turn them into research that has the potential to transform immunotherapy treatments.
Meet Our 2022 Awardees
NO. OF AWARDS SINCE 2016
TOTAL AMOUNT AWARDED
Since our inception, we’ve been planning for the future. And the brightest young investigators in cancer immunotherapy are the future. In 2016, we launched the Parker Scholars, Parker Bridge Fellows and Parker Senior Fellows to support the most ambitious early career researchers. Risk-taking is required. New thinking is mandatory. We challenge them to explore their boldest ideas to propel the field forward. We equip them with cutting-edge tools and technologies. We give them access to data from clinical trials and pre-published papers. We connect them with leading researchers and their peers in cancer immunotherapy. We do our part so they can focus on advancing their science. The end goal: a future where we don’t have to fear cancer.